Nasopharyngoscope Market Expected to Reach US$ 813.4 Million with Growing at an 8.1% CAGR by 2034 | Fact.MR Report
Rockville, MD, Nov. 18, 2024 (GLOBE NEWSWIRE) — According to Fact.MR, a market research and competitive intelligence provider, the global nasopharyngoscope market is estimated to reach a valuation of US$ 373.3 million in 2024 and is expected to grow at a CAGR of 8.1% during the forecast period of (2024 to 2034).
The global nasopharyngoscope market is set to see remarkable growth spur further by the increasing demand for minimally invasive diagnostic techniques in ENT treatment. Due to rising cases of respiratory diseases, chronic sinusitis, sleep apnea, and other related conditions, nasopharyngoscopes-face increasing demand for them as key instruments used in looking at and diagnosing nasal passages, pharynx, and larynx conditions.
Market is driven by technological advancements in product development, increased adoption of video nasopharyngoscopes, and healthcare expenditure. Growing demand for such devices is also connected with increases in the global geriatric population and a rise in outpatient and office-based ENT procedures where such equipment is in common use.
The introduction of advanced systems by major medical device companies has led to some newsworthy market developments in terms of new partnerships and product launches. One such recent development involves the partnership between major healthcare companies in developing next-generation diagnostic nasopharyngoscopes that would allow for real-time imaging, further improving the precision and safety of the patient. Such innovations address the increasingly complex nature of upper respiratory tract disorders, enabling clear pathways toward more sensitive, non-invasive diagnostics
Ongoing innovation within the imaging technology, whereby integration of high-definition cameras together with features such as real-time video has considerably increased the diagnostic capability of the nasopharyngoscopes. Other companies are trying to manufacture systems that are much more compact and available at low cost while being easy to operate, hence extending their usability in office-based infrastructure and community clinics.
For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=10429
There is an emerging prevalence of chronic sinusitis, sleep apnea disorders, and allergic rhinitis, which demands efficient diagnostic tools. The rise in the geriatric population along with other environmental factors such as pollution has contributed to a rise in upper respiratory diseases, thus boosting demand in the market.
Less invasive diagnostic procedures now characterize the new standard of care in otolaryngology, given the reduced risk, faster recovery time, and comfort for the patients. The nasopharyngoscope, especially the diagnostic type, has been an invaluable tool in outpatient clinics and has tended to minimize the use of more invasive surgical alternatives.
Most the developing regions are investing in healthcare infrastructure. Parts of Asia and Latin America are such geographies that are investing in healthcare infrastructure development. Such infrastructural growth, coupled with increasing access to higher-end medical devices, is likely to drive adoption of nasopharyngoscope across hospitals and diagnostic centres in these markets
Key Takeaways from Market Study
- The global nasopharyngoscope market is projected to grow at 1% CAGR and reach US$ 813.4 million by 2034
- The market created an opportunity of US$ 70.2 million growing at a CAGR of 8% between 2019 to 2023
- North America is a prominent region that is estimated to hold a market share of 6% in 2034
- Predominating market players include Olympus Corporation, Fujifilm Holdings Corporation, and Karl Storz SE & Co. KG.
- Reusable nasopharyngoscopes under usage type are estimated to grow at a CAGR of 1% creating an absolute $ opportunity of US$ 385.1 million between 2024 and 2034
“Advancements in digitalization and minimally invasive procedures to boost global market demand” says a Fact.MR analyst.
Leading Players Driving Innovation in the Nasopharyngoscope Market:
Medtronic plc; Stryker Corporation; Boston Scientific Corporation; Richard Wolf GmbH; Cook Medical Incorporated; Olympus Corporation; Fujifilm Holdings Corporation; Karl Storz SE & Co. KG; Entellus Medical (Stryker Corporation); Smith & Nephew plc; Ambu A/S; Conmed Corporation; Happersberger otopront GmbH; EndoMed Systems GmbH.; Other Prominent Players.
Market Development:
With recent strategic collaborations and product launches, some of the leading companies are well placed to capture the nasopharyngoscope market.
ABC Medical Technologies has just introduced a new generation of video nasopharyngoscope with integrated AI diagnostic capabilities that will help ENT specialists find abnormalities in real time. Such a step is not surprising, as it corresponds with the ambitions of the company to become a global leader in endoscopy technology by 2026.
In light of the above, collaboration by DEF Healthcare Systems with XYZ Diagnostics to jointly develop a new range of disposable nasopharyngoscopes targeted at community clinics and ambulatory centers is functional. The product line focuses on the benefit of reduction in cross-contamination risks that is driving demand for single-use medical devices within outpatient care.
Nasopharyngoscope markets continue to present growth opportunities; companies establish ambitious yet achievable goals to capture more market share.
Large companies are beginning to target growth markets in Asia-Pacific and Latin America due to increased development in the healthcare infrastructure of these regions. Partnerships with local distributors and healthcare providers enable manufacturers to reach such high-growth markets. For instance, DEF Healthcare Systems plans to achieve 15% market share in Southeast Asia within the next three years by co-operating with the partner and producing products to their likings.
Companies are developing new product lines targeting various end-user segments, such as hospitals, diagnostic centers, and office-based procedures. The focus on the development of reusable and disposable varieties allows manufacturing companies to target cost-sensitive institutions, as well as infection-conscious ones. For example, ABC Medical Technologies plans to launch a wide range of reusable and disposable nasopharyngoscopes before the end of 2025 to meet wider market requirements.
A lot of investment is being laid in integrating AI and machine learning into nasopharyngoscopes. AI-based systems are already used by companies to support early detection, facilitating better diagnostic precision for ENT conditions. DEF Healthcare Systems is set to introduce an AI diagnostic system that would alter the use of nasopharyngoscope in office-based and hospital settings by 2028.
Major manufacturers are eyeing a 20% increase in global market share by 2030, driven by aggressive marketing strategies, product launches, and expansion into new geographies, especially emerging economies where healthcare expenditure is on the rise.
The growth of the nasopharyngoscope market is foreseen to continue further, wherein strategies related to innovation and expansion would play an imperative role. As companies begin to internally strengthen their product portfolios and utilize new technologies, the segment could only reach new heights by 2032. Some major focus areas of the leading players in the industry for recent developments include AI integration, product diversification, and geographical expansion.
Nasopharyngoscope Industry News:
- In July 2022, The EES 100 is a nasopharyngoscope from Medimaging Integrated Solution Inc., which has secured FDA approval. This is a flexible nasopharyngoscope with completely integrated LEDs and a micro camera module that find their application in minimally invasive procedures.
- In June 2021, Fujifilm Corporation Announced system integration platform designed exclusively for endoscopy suite including a nasopharyngoscope, to improve image and data integration in the endoscopy suite.
Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=S&rep_id=10429
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global nasopharyngoscope market, presenting historical data for 2019 to 2023 and forecast statistics for 2024 to 2034.
The study reveals essential insights on the basis of the global nasopharyngoscopes market analysis, by product type systems (flexible nasopharyngoscopes, [flexible video nasopharyngoscopes, flexible fiberoptic nasopharyngoscopes], rigid nasopharyngoscopes [rigid video nasopharyngoscopes, rigid fiberoptic nasopharyngoscopes]), accessories (light sources, sheaths and cannulas, biopsy forceps, suction catheters, insufflation tubes, video cables and connectors, cleaning and sterilization systems, monitor and display systems, irrigation systems, endoscope holders), by application (diagnostic nasopharyngoscopes [nasal obstructions evaluation, chronic/recurrent sinusitis & rhinitis, adenoid hypertrophy, vocal cord and laryngeal disorders, sleep apnea evaluation, epistaxis detection, tumor detection] surgical nasopharyngoscopes [endoscopic sinus surgery, adenoidectomy, nasopharyngeal tumors biopsy and removal, septoplasty, laser-assisted uvulopalatopharyngoplasty (LAUP), foreign body removal, epistaxis cauterization, nasal bones and cartilage repair surgery, turbinate reduction surgery), by usage type (reusable nasopharyngoscopes and disposable nasopharyngoscopes), by end user (hospitals, diagnostic centers, office-based settings, ambulatory surgical centers, community/specialty clinics) and across major regions of the world (North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia, and Pacific, Middle East & Africa).
Checkout More Related Studies Published by Fact.MR Research:
The global prescription delivery service market is estimated to touch a valuation of US$ 192.32 million in 2024. The market has been forecasted to expand at a CAGR of 14.3% to achieve a size of US$ 734.15 million by the end of 2034.
According to a new industry report released by Fact.MR, turnover of the global endovascular stent market is estimated at US$ 1.32 billion in 2024 and is forecasted to expand at 8.5% CAGR to achieve a value of US$ 2.99 billion by the end of 2034.
Fact.MR in its new report stated that the global ceftriaxone sodium (API) market is estimated to touch a valuation of US$ 339.44 million in 2024 and is further forecasted to reach a value of US$ 821.62 million by 2034-end. Demand is projected to increase at a notable CAGR of 9.2% throughout the projection period (2024 to 2034).
The global Cas9 nuclease market is estimated at US$ 217.95 million in 2024. The market has been projected to rise at a double-digit CAGR of 14.6% and reach a size of US$ 854.97 million by the end of 2034.
The Global Factor XIII Deficiency Treatment Market will be valued at US$ 210.3 million in 2023 and has been forecasted to expand at a noteworthy CAGR of 5.8% to end up at US$ 400.7 Million by 2034.
About Us:
Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning. With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team: sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Leave a Reply